Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU in talks to secure Sanofi deal for coronavirus vaccine

07/31/2020 | 11:56pm EDT
FILE PHOTO: Sanofi logo is seen in Paris

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine for the 27-country European Union.

Armed with an emergency fund of more than 2 billion euros (£1.80 billion), the European Commission wants to strike deals with up to six drugmakers for their vaccines for their 450 million citizens against the coronavirus that has killed 674,000 people worldwide.

The Commission said the aim of the talks with Sanofi was to clinch an advance purchase deal.

"The envisaged contract with Sanofi would provide for an option for all EU Member States to purchase the vaccine," the Commission said in a statement.

"It is envisaged that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU member states."

A Commission spokesman said he could not comment on when a deal would be announced and the possible price for the vaccine, calling it a quite promising step towards an eventual agreement.

Sanofi is working on two vaccine projects including one in partnership with GlaxoSmithKline.

The companies said the doses would be manufactured in European countries including France, Belgium, Germany and Italy.

Sanofi is leading the clinical development of the vaccine and expects to start a trial by the end of this year.

Earlier this week, EU talks with Sanofi, Pfizer and Johnson & Johnson hit an impasse over price, payment method and potential liability costs, EU officials told Reuters.

Other pharmaceutical companies talking to the EU include France's Valneva, Moderna and biotech firms BioNTech and Germany's CureVac.

By Foo Yun Chee


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 2.28% 132.6 Delayed Quote.59.03%
GLAXOSMITHKLINE PLC 0.14% 1289.6 Delayed Quote.-4.04%
MODERNA, INC. 6.89% 160.03 Delayed Quote.43.30%
PFIZER INC. 0.03% 37.17 Delayed Quote.0.43%
SANOFI -0.08% 84 Real-time Quote.6.82%
VALNEVA SE -1.58% 12.46 Real-time Quote.63.35%
All news about GLAXOSMITHKLINE PLC
04/12SECTOR UPDATE : Health Care Stocks Slip as Midday Gains Evaporate
MT
04/12SECTOR UPDATE : Health Care Stocks Drifting Higher This Afternoon
MT
04/12ZENTALIS PHARMACEUTICALS  : Unveils Clinical Collaboration Deal With GlaxoSmithK..
MT
04/12GLAXOSMITHKLINE  : JP Morgan reiterates its Neutral rating
MD
04/12Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline
DJ
04/08GLAXOSMITHKLINE  : 2021 Q1 pre announcement aide memoire
PU
04/07GLAXOSMITHKLINE  : Gsk Group company names and addresses PDF - 169.3KB
PU
04/06GLAXOSMITHKLINE  : GSK announces Dr Anne Beal to join the Board as Non-Executive..
PU
04/06GLAXOSMITHKLINE PLC  : Nomination
CO
04/01LANNETT  : Submits Abbreviated New Drug Application to FDA for Generic Asthma Me..
MT
More news
Financials
Sales 2021 33 755 M 46 521 M 46 521 M
Net income 2021 3 797 M 5 233 M 5 233 M
Net Debt 2021 21 381 M 29 467 M 29 467 M
P/E ratio 2021 16,7x
Yield 2021 6,18%
Capitalization 64 253 M 88 637 M 88 554 M
EV / Sales 2021 2,54x
EV / Sales 2022 2,38x
Nbr of Employees 94 066
Free-Float 92,5%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 1 521,25 GBX
Last Close Price 1 287,80 GBX
Spread / Highest target 59,2%
Spread / Average Target 18,1%
Spread / Lowest Target -25,1%
EPS Revisions
Managers and Directors
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-4.04%88 143
JOHNSON & JOHNSON1.33%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.43%207 285
NOVARTIS AG-4.61%195 170
MERCK & CO., INC.-6.56%193 467